Epigenetic therapy in Myelodysplasia and Chronic Myelomonocytic Leukaemia

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1024364

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The myelodysplastic syndromes (MDS) are a group of disorders that are characterised by impaired blood production and progression to leukaemia within a few months to several years from diagnosis. We will use bone marrow blood stem cells collected from patients with myelodysplasia to study how normal stem cells transform into abnormal stem cells. We hope to identify molecular pathways that are disrupted during this transformation to rationally design drugs to better treat these common disorders.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2014

Funding Scheme: Project Grants

Funding Amount: $676,779.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Haematological Tumours

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer cell biology | cancer therapy | gene transcription | leukaemia | molecular basis of disease

Related Links